BAY 1193397

Drug Profile

BAY 1193397

Alternative Names: BAY-1193397

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Class Cardiovascular therapies; Vascular disorder therapies
  • Mechanism of Action Alpha 2c adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Peripheral arterial disorders

Most Recent Events

  • 25 May 2017 Phase-II clinical trials in Peripheral arterial disorders (In adults, In the elderly) in United Kingdom (PO) (NCT03128320)
  • 28 Apr 2017 Bayer plans a phase II trial in Peripheral arterial disorders (In adults, In the elderly) in United Kingdom (PO) (NCT03128320)
  • 21 Apr 2017 Preclinical trials in Peripheral arterial disorders in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top